IOVA catalyst calendar

IOVANCE BIOTHERAPEUTICS, INC.

Upcoming catalysts
9
Cash runway
12.4 months
Cash & investments
$298M
Phase 3 programs
1

IOVANCE BIOTHERAPEUTICS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 9 upcoming events on record.

Cash runway is approximately 12.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 6 concluded trials, 50% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 5, 2026 est. Next quarterly earnings (projected) Earnings —
September 15, 2027 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer Trial Milestone Phase 1/Phase 2
December 15, 2027 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma Trial Milestone Phase 2
March 1, 2028 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. Trial Milestone Phase 3
May 15, 2028 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. Trial Milestone Phase 2
December 15, 2030 Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Trial Milestone Phase 2
June 15, 2032 A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel Trial Milestone Phase 1/Phase 2
September 1, 2033 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Trial Milestone Phase 2
March 15, 2034 A Study of IOV-5001 in Adults With Advanced Solid Tumors Trial Milestone Phase 1/Phase 2

Track IOVA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open IOVA in the tracker

Recent history

DateEventTypePhase
October 5, 2026 8-K filed: Other event Filing —
September 29, 2026 8-K filed: Other event Filing —
August 6, 2026 Quarterly results filed (8-K) Earnings —
August 6, 2026 8-K filed: Other event Filing —
July 15, 2026 Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants Trial Milestone Phase 1
July 2, 2026 8-K filed: Other event Filing —
June 10, 2026 8-K filed: Other event Filing —
May 7, 2026 Quarterly results filed (8-K) Earnings —
March 20, 2026 8-K filed: Leadership change Corporate —
February 24, 2026 Quarterly results filed (8-K) Earnings —
February 20, 2026 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Trial Milestone Phase 2
January 9, 2026 8-K filed: Other event Filing —
November 6, 2025 Quarterly results filed (8-K) Earnings —
August 29, 2025 8-K filed: Other event Filing —
August 22, 2025 8-K filed: Material agreement Corporate —
August 22, 2025 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma Trial Milestone Phase 2
August 19, 2025 8-K filed: Other event Filing —
August 7, 2025 Quarterly results filed (8-K) Earnings —
July 15, 2025 8-K filed: Leadership change, Other event Corporate —
July 3, 2025 8-K filed: Leadership change Corporate —
June 13, 2025 8-K filed: Leadership change Corporate —
May 8, 2025 Quarterly results filed (8-K) Earnings —
November 11, 2024 Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL Trial Milestone Phase 1
October 24, 2024 Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma Trial Milestone Phase 2
August 8, 2022 Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.